Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - Bellerophon Therapeutics, Inc. | blph12312015ex311.htm |
| EX-31.2 - EXHIBIT 31.2 - Bellerophon Therapeutics, Inc. | blph12312015ex312.htm |
| EX-23.1 - EXHIBIT 23.1 - Bellerophon Therapeutics, Inc. | blph12312015ex231.htm |
| EX-10.43 - EXHIBIT 10.43 - Bellerophon Therapeutics, Inc. | blph12312015ex1043.htm |
| EX-10.44 - EXHIBIT 10.44 - Bellerophon Therapeutics, Inc. | blph12312015ex1044.htm |
| 10-K - 10-K - Bellerophon Therapeutics, Inc. | blph12312015-10k.htm |
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Bellerophon Therapeutics, Inc. (the “Company”), a Delaware corporation (the "Company"), does hereby certify, to such officer's knowledge, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 21, 2016 | By: | /s/ Jonathan M. Peacock |
Jonathan M. Peacock Chief Executive Officer (Principal Executive Officer) | ||
Date: March 21, 2016 | By: | /s/ Fabian Tenenbaum |
Fabian Tenenbaum Chief Financial Officer and Chief Business Officer (Principal Financial Officer) | ||